A Phase 1 interventional study of ODM-201 300 mg tablet and intravenous14C-ODM-201 in Healthy, sponsored by Orion Corporation, Orion Pharma. Completed at 1 site in United Kingdom. Open to male participants aged 50 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-06-23.
Sponsored by Orion Corporation, Orion Pharma · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A study to investigate absolute bioavailability of ODM-201 and to determine the mass balance and routes of excretion of ODM-201 in healthy volunteers.
6 healthy male subjects will be enrolled in part 1 and part 2 of the study, respectively
Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single oral 300 mg tablet of ODM-201 followed by single intravenous 100 microg of 14C-ODM-201 containing not more than 37 kBq (1000 nCi)14C
Drug: ODM-201 300 mg tablet · Drug: intravenous14C-ODM-201
A single oral solution of 300 mg 14C-ODM-201 containing no more than 6.3 MBq (171 microCi) 14C
Drug: 300 mg 14C-ODM-201 oral solution
Amount of 14C-ODM-201 dose excreted and cumulative amount excreted in urine and faeces and total. Amount excreted and cumulative amount excreted in urine, faeces and total expressed as a percentage of the administered dose.
Time frame: Urine and faecal samples are collected baseline (Day-1) 72 h post-dose after IV dosing and up-to 14 day post-dose after oral solution dosing
Metabolite profile of 14C-ODM-201 in plasma, urine and faeces
Time frame: up to 14 days post-dose after oral solution dosing
Maximum concentration (Cmax) of 14C-radioactivity in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 14 day post-dose after oral solution dosing
Time to maximum concentration (tmax) of 14C-radioactivity in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 14 day post-dose after oral solution dosing
Area under the plasma concentration-time curve (AUC(0-t)) of 14C-radioactivity in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 14 day post-dose after oral solution dosing
Area under the plasma concentration-time curve (AUC(0-infinity)) of 14C-radioactivity in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 14 day post-dose after oral solution dosing
Half life (t1/2) of 14C-radioactivity in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 14 day post-dose after oral solution dosing
Maximum concentration (Cmax) of ODM-201 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing
Time to maximum concentration (tmax) of ODM-201 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing
Area under the plasma concentration-time curve (AUC(0-t)) of ODM-201 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing
Area under the plasma concentration-time curve (AUC(0-infinity)) of ODM-201 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing
Half life (t1/2) of ODM-201 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing
Maximum concentration (Cmax) of metabolite ORM 15341 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing
Time to maximum concentration (tmax) of metabolite ORM 15341 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing
Area under the plasma concentration-time curve (AUC(0-t)) of metabolite ORM 15341 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing
Area under the plasma concentration-time curve (AUC(0-infinity)) of metabolite ORM 15341 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing
Half life (t1/2) of metabolite ORM 15341 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 216 h post-dose after oral solution dosing
Maximum concentration (Cmax) of metabolite 14C-ORM 15341 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing
Time to maximum concentration (tmax) of metabolite 14C-ORM 15341 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing
Area under the plasma concentration-time curve (AUC(0-t)) of metabolite 14C-ORM 15341 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing
Area under the plasma concentration-time curve (AUC(0-infinity)) of metabolite 14C-ORM 15341 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing
Half life (t1/2) of metabolite 14C-ORM 15341 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing
Maximum concentration (Cmax) of 14C-ODM-201 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing
Time to maximum concentration (tmax) of 14C-ODM-201 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing
Area under the plasma concentration-time curve (AUC(0-t)) of 14C-ODM-201 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing
Area under the plasma concentration-time curve (AUC(0-infinity)) of 14C-ODM-201 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing
Half life (t1/2) of 14C-ODM-201 in plasma
Time frame: The samples were taken 72 h post-dose after IV dosing
Maximum concentration (Cmax) of 14C-radioactivity in whole blood
Time frame: The samples were taken 24 h post-dose after oral solution dosing
Time to maximum concentration (tmax) of 14C-radioactivity in whole blood
Time frame: The samples were taken 24 h post-dose after oral solution dosing
Area under the plasma concentration-time curve (AUC(0-t)) of 14C-radioactivity in whole blood
Time frame: The samples were taken 24 h post-dose after oral solution dosing
Renal elimination for ODM-201 in urine
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 14 d post-dose after oral solution dosing
Renal elimination for 14C-ODM-201 in urine
Time frame: The samples were taken up-to 14 d post-dose after oral solution dosing
Fraction absorbed (FA) of total radioactivity based on urinary recovery of total radioactivity for both IV and oral dosing
Time frame: The samples were taken 72 h post-dose after IV dosing and up-to 14 d post-dose after oral solution dosing
Adverse events
Time frame: Collected 7 days post-dose in part 1 and up to 14 days post-dose in part 2
Physical examination
Full physical examination
Time frame: Assessed at screening, pre-dose, at discharge from the study centre (72 h and 7 d post-dose in part 1 and latest at 14 d post-dose in part 2)
Blood pressure
Time frame: Assessed at screening, pre-dose, 3 h, 5 h, 12 h, 24 h, 36 h and 48 h post-dose and at discharge from the study centre (72 h post-dose in part 1 and latest at 14 d post-dose in part 2) and in addition in part 1 7 d post-dose
Heart rate
Time frame: Assessed at screening, pre-dose, 3 h, 5 h, 12 h, 24 h, 36 h and 48 h post-dose and at discharge from the study centre (72 h post-dose in part 1 and latest at 14 d post-dose in part 2) and in addition in part 1 7 d post-dose
Oral temperature
Time frame: Assessed at screening, pre-dose, 3 h, 5 h, 12 h, 24 h, 36 h and 48 h post-dose and at discharge from the study centre (72 h post-dose in part 1 and latest at 14 d post-dose in part 2) and in addition in part 1 7 d post-dose
12-lead ECG
Time frame: Assessed at screening, pre-dose, 3 h, 5 h, 12 h, 24 h, 36 h and 48 h post-dose and at discharge from the study centre (72 h post-dose in part 1 and latest at 14 d post-dose in part 2) and in addition in part 1 7 d post-dose
Clinical chemistry
Alanine Aminotransferase, Albumin, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin (Total), Calcium, Creatinine, Creatinine clearance, Lactate dehydrogenase, Potassium, Sodium and Urea
Time frame: Assessed at screening, pre-dose, 24 h and 48 h post-dose and 7 d post-dose in part 1 and latest at 14 d post-dose in part 2
Haematology
Basophils, Eosinophils, Haematocrit, Haemoglobin, Lymphocytes, MCH, MCHC, MCV, Monocytes, Neutrophils, Red Blood Cell Count, White Blood Cell Count and Thrombocytes
Time frame: Assessed at screening, pre-dose, 24 h and 48 h post-dose and 7 d post-dose in part 1 and latest at 14 d post-dose in part 2
Urinalysis
Leucocytes, protein, erythrocytes, glucose and specific gravity
Time frame: Assessed at screening, pre-dose, 24 h and 48 h post-dose and 7 d post-dose in part 1 and latest at 14 d post-dose in part 2
The record gives a start of Mar 2015, a primary completion of May 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Darolutamide
Orion Corporation, Orion Pharma →